Sleep disturbance linked to amyloid in brain areas affected by Alzheimer's disease

Numerous studies have shown the importance of sleep and the effect that sleep deprivation can have on our brains. Sleep apnea is associated with cognitive dysfunction across the lifespan and both untreated apnea and sleep disturbance are associated with increased cognitive dysfunction in patients with Alzheimer's disease. Evaluating physical changes in the brain and how they are related to sleep quality can help determine the extent to which sleep can provide a window on brain function and pathology.

Using positron emission tomography (PET) scanning with a tracer that visualizes deposits of amyloid, a protein that is elevated in the brains of Alzheimer's disease patients, Ruth Benca and her colleagues at the University of Wisconsin-Madison studied the relationship between sleep quality and brain amyloid levels in a group of 98 cognitively healthy volunteers, 50-73 years of age.

The subjects, who were participants in the Wisconsin Registry for Alzheimer's Prevention, completed questionnaires about their sleep and problems related to it. Those who reported greater sleepiness showed greater amyloid acumulation in areas of the cerebral cortex that are heavily affected in Alzheimer's disease ─ the supramarginal and frontal medial orbital areas. Higher amyloid in these regions was also linked to less restful sleep and more sleep problems.

Although it is tantalizing to speculate that the link between sleep disturbances and amyloid deposition in the brain may help us identify an early, modifiable marker for Alzheimer's disease, it is too soon to draw that conclusion. “We still need to determine whether sleep disturbance promotes amyloid deposition in the brain, or if a neurodegenerative process produces disordered sleep”, commented Dr. Benca. Future work is needed to answer that question and to determine whether interventions that improve sleep can prevent brain changes that lead to Alzheimer's disease.

This research was supported by funding from the National Institutes of Health: National Institute on Aging, National Institute of General Medical Sciences, and the Clinical and Translational Science Award Program.

Public relations Contact

Susan Lambert Smith
ssmith5@uwhealth.org

ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including four Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances.